- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01735474
Results of Manual Therapy on Pulmonary Parameters
Manual Therapy Results on Pulmonary Function and Musculoskeletal Movement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized controlled trial. Participants are classified in two groups and they are assessed using pulmonary functions parameters and thoracic and spinal movements.
There are two interventions: placebo and a manual technique. Participants will be assessed again at the end of the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain
- Faculty of Health Sciences. University of Granada
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects with respiratory conditions
- Must be able to do spirometry
Exclusion Criteria:
- subjects with acute processes in their pathologies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
30 people are recruited in order to the inclusion criteria for the study.
Placebo controlled.
|
Usual care
Other Names:
|
|
Active Comparator: Manual technique
30 people are recruited in order to the inclusion criteria for the study.
Experimental group.
|
A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system. The manual technique includes: stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
spirometry parameters
Time Frame: Baseline, 6 months
|
Change from baseline to postintervention in spirometry parameters (Vital capacity, Forced expiratory volume in the first second (FEV1), Tidal volume)using a spirometer as recommended by the American Thoracic Society.
|
Baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
thoracic movement
Time Frame: at baseline, 6 months
|
Changes from baseline to postintervention in thoracic movement, measured by tape measure in 3 thoracic levels.
|
at baseline, 6 months
|
|
Changes on Functionality scores
Time Frame: baseline, 6 months
|
Functional status questionnaire used before and after intervention to measure functionality scores change.
|
baseline, 6 months
|
|
Changes on cardiorespiratory capacity
Time Frame: baseline, 6 months
|
Changes on cardiorespiratory capacity measured by 6MWT (6 minutes walking test)at baseline and post intervention.
|
baseline, 6 months
|
|
spinal movement
Time Frame: at baseline, 6 months
|
Changes from baseline to postintervention in spinal movement, measured by Range of motion with goniometer.
|
at baseline, 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carmen M Valenza, PH MD, Universidad de Granada
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DF0035UG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Disease
-
Altesa Biosciences, Inc.CompletedHealthy | Pulmonary Disease | COPD | Respiratory Disease | Lower Respiratory DiseaseUnited States
-
Altesa Biosciences, Inc.Virtus Respiratory ResearchCompletedRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionInfections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditionsUnited Kingdom
-
FisioRespiraciónUniversidad Complutense de Madrid; NeumomadridUnknownAcute Disease RespiratorySpain
-
Società Italiana di Allergologia, Asma e Immunologia...Società Italiana di Allergologia e Immunologia Pediatrica (SIAIP)Recruiting
-
Rochester General HospitalCompletedAspirin-exacerbated Respiratory DiseaseUnited States
-
SOS Oxygene MediterraneeRecruitingExercise | Chronic Respiratory DiseaseFrance
-
West Park Healthcare CentreEnrolling by invitation
-
KorianCompletedChronic Respiratory DiseaseFrance
-
Rambam Health Care CampusUnknown
-
Larissa University HospitalRecruitingRespiratory Disease (Clinically Stable Individuals - Patients Recovered From Respiratory Disease)Greece
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States